Apple's price hikes are a warning shot, not a one-time fix

Apple raised prices by up to 20% on MacBooks, iPads, and other hardware, blaming surging memory and storage chip costs driven by AI data center demand.

The price increases are a symptom of a structural cost problem that does not stop at laptops — if memory chip prices rise as sharply as forecast this year, Apple faces the same painful math on the iPhone, its most important product.

Polestar's U.S. ban shows how fast politics can redraw the EV landscape

The Trump administration announced it will ban Polestar from the U.S. market starting with the 2027 model year under rules targeting automakers with Chinese ownership ties, effectively shutting the Swedish-Chinese brand out of one of its key sales markets.

The move is a sharp reminder that connected-vehicle rules can function as a market exit order — and any EV brand with Chinese investment in its structure is now reading the fine print of its own exposure.

Moderna's cell therapy announcement is the most credible growth signal the company has sent in months

Moderna led the S&P 500 on Friday after unveiling a new cell therapy program, with the gain driven by that specific announcement rather than the broader rotation into healthcare stocks.

For a company that has spent months searching for a post-COVID identity, a concrete pipeline expansion into cell therapy gives investors something to price beyond vaccine revenue — and the market's reaction suggests they were hungry for exactly that.